Lumos Diagnostics Holdings Limited (LDXHF) Discusses CLIA Waiver Clearance for FebriDx, Capital Raise, and Commercialization Strategy Transcript

SA Transcripts159.16K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Lumos Diagnostics Holdings Limited (LDXHF) Discusses CLIA Waiver Clearance for FebriDx, Capital Raise, and Commercialization Strategy March 30, 2026 6:00 PM EDT Company Participants George KopsiaftisDouglas Ward - CEO, MD & DirectorPaul Kase - Senior Vice President of Commercial OperationsTracy Weimar - Company Secretary Presentation George Kopsiaftis Good morning, everyone, and welcome to the Lumos Diagnostics investor briefing to discuss the recent granting of CLIA for FebriDx and the capital raise. My name is George Kopsiaftis, and I'll be your moderator for today. This webinar is being recorded today and will be available on Lumos' website. With us this morning, we have Lumos Diagnostics' CEO, Doug Ward; we have Paul Kase, Chief Commercial Officer; and Tracy Weimar, the Company Secretary. Good morning to you all. Douglas WardCEO, MD & Director Good morning, George. Paul KaseSenior Vice President of Commercial Operations Morning, George.

George Kopsiaftis Good morning. The format for today is for Doug and Paul to walk you through the presentation that was released to the ASX on Friday. This presentation should take around 30 minutes. This will be followed by a question-and-answer session, and we plan to wrap up in 45 minutes. [Operator Instructions] And with that, I'd now like to hand it over to Doug and Paul to get us started. Douglas WardCEO, MD & Director All right. Thank you very much, George. I really appreciate it, and welcome, everyone, to this investor presentation. Boy, I'd tell you, I'm so thrilled to speak to you today, such a momentous time for Lumos Diagnostics and really stepping into the next, if you will, plateau for the company with the announcement of the CLIA waiver and the capitalization of the company. So we're going to go through this deck, which is an update on the business and what you can expect going forward relative to commercialization as well as